• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Halozyme Therapeutics (HALO) Adding Dealmaker Appelhans To Bolster ENHANZE Partnerships

    Simply Wall St·09/01/2026 05:16:24
    Listen to the news
    • In August 2026, Halozyme Therapeutics appointed Dannielle Appelhans, an executive with more than 20 years of biotech and pharma leadership in operations, manufacturing, and supply chain, to its Board of Directors.
    • Her track record leading complex manufacturing organizations and negotiating large-scale pharma collaborations, including a potential US$1.00 billion deal at COUR Pharmaceuticals, may strengthen Halozyme’s efforts to scale its ENHANZE-based partnerships.
    • With this new operational and partnership expertise on the board, we'll now assess how the appointment could influence Halozyme's investment narrative.

    Find 45 companies with promising cash flow potential yet trading below their fair value.

    Halozyme Therapeutics Investment Narrative Recap

    To own Halozyme, you need to believe in the durability of its ENHANZE royalty model and partners’ continued shift toward subcutaneous delivery. In the near term, the main catalyst is execution on existing and new ENHANZE collaborations, while key risks center on patent challenges and partner concentration. The appointment of Dannielle Appelhans looks supportive of operational scale-up, but it does not materially change those immediate catalysts or headline risks by itself.

    Among recent developments, the expanded ENHANZE collaboration with Takeda for vedolizumab (ENTYVIO) stands out as most relevant. It highlights how Halozyme is still adding large, global partners to its royalty base at the same time it is refreshing its leadership bench. Together with Appelhans joining the board, this reinforces the focus on scaling complex pharma partnerships, which remains central to how short term catalysts around revenue growth and earnings visibility might play out.

    Yet beneath this growth story, investors should be aware of how IP challenges and ENHANZE concentration could...

    Read the full narrative on Halozyme Therapeutics (it's free!)

    Halozyme Therapeutics' narrative projects $2.1 billion revenue and $1.1 billion earnings by 2029.

    Uncover how Halozyme Therapeutics' forecasts yield a $86.89 fair value, a 18% downside to its current price.

    Exploring Other Perspectives

    HALO 1-Year Stock Price Chart
    HALO 1-Year Stock Price Chart

    While consensus assumes improving earnings toward about US$1.2 billion by 2029, the lowest analysts focus on ENHANZE reliance and patent timing, suggesting outcomes could differ sharply from today’s expectations.

    Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth 18% less than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.